Brazil Injectable Drugs Market
- 2026 年市場規模
- USD 11,920 Mn
- 2033 年預估規模
- USD 20,950 Mn
- 年複合成長率 CAGR
- 8.4%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Brazil Injectable Drugs Market, By Product Type (Pre-filled syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, and Others), By Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-Thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, and Others), By Mode of Delivery (Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), Others (Epidural and Intrathecal))
報告摘要
Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site. Injectable delivery facilitates rapid absorption of drug from various route of administration such as subcutaneous, intravenous, and intramuscular. Injectable delivery increases the bioavailability of the drug at the systemic circulation. The increasing prevalence of chronic diseases, technological advancements, demand for individual therapy, awareness about drug metabolism among the population, and requirement of controlled drug release are the major factors driving the growth of the Brazil injectable drugs market for hospitals & ambulatory settings.
Brazil injectable drugs market for hospitals & ambulatory settings is estimated to be valued at US$ 7,960.0 Mn in 2021 and is expected to increase to US$ 17,858.5 Mn by 2028, witnessing a CAGR of 8.4% during the forecast period.
Market Dynamics
Increasing government initiatives in the healthcare sector of Brazil, rising drug launches and approvals, increasing prevalence of chronic diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Brazil injectable drugs market for hospitals & ambulatory settings.
The healthcare sector of Brazil is witnessing significant reforms in recent times owing to increasing initiatives by the government, agreements between multinational pharmaceutical companies and rising healthcare expenditure which is driving growth of the Brazil injectable drugs market for hospitals and ambulatory settings.
For instance, in June 2020, the government of Brazil announced an agreement with Oxford University and pharmaceutical company, AstraZeneca, to produce a promising coronavirus vaccine that is undergoing tests. The Brazilian Health Ministry said in a press conference that the country will pay US$ 127 million and receive material to produce 30.4 million doses in two batches in December and January.
Furthermore, in June 2019, government of the state of São Paulo, Brazil announced that they are seeking volunteers to test a new injectable drug preventing HIV infection using long-term injections as an alternative to the daily oral medication.
Moreover, increasing vaccination drives for certain diseases are also expected to aid growth of the Brazil Injectable drugs market for hospitals and ambulatory settings. For instance, in March 2020, Brazil initiated its National Flu Vaccination Campaign in three phases against influenza. The vaccine is indicated for anyone over 6 months of age, except those who have had allergic reactions to previous doses.
Key features of the study
• This report provides an in-depth analysis of the Brazil injectable drugs market for hospitals & ambulatory settings market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Brazil injectable drugs market for hospitals & ambulatory settings, based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Becton, Dickinson and Company, Pfizer, Inc., Novo Nordisk A/S, Gerresheimer AG, B. Braun Medical Inc., Grifols S.A, Baxter International, Inc., Fresenius Kabi AG, Mylan N.V., Bayer AG, F. Hoffmann-La Roche AG, Farmoquimica S.A., Novartis International AG, Eli Lily and Company, União Química Farmacêutica, Nacional S.A., Cristália, Aspen Pharmacare Holdings Limited, Blau Farmaceutica S.A., Halex Istar Indústria, Farmacêutica SA, Eurofarma, Ache Laboratorios Farmaceuticos SA, Laboratorio Teuto Brasileiro S/A, EMS Pharma, and Hipolabor Farmaceutica Ltda.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Brazil injectable drugs market for hospitals & ambulatory settings report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Brazil injectable drugs market for hospitals & ambulatory settings
Market Segmentation
• By Product Type Insights (Revenue, US$ Mn, 2020 - 2033)
o Pre-filled syringes
o Auto-injectors
o Pre-filled Pens
o Pre-mixed IV Bags
o Others
• By Drug Class Insights (Revenue, US$ Mn, 2020 - 2033)
o Anesthesia
o Antibiotics
o Antidotes
o Antiemetic
o Anti-infective
o Anti-Thrombolytic
o Muscle Relaxant
o Non Opioids
o Opioids
o Sedatives
o Others
• By Mode of Delivery Insights (Revenue, US$ Mn, 2020 - 2033)
o Intramuscular (IM)
o Intravenous (IV)
o Subcutaneous (SC)
o Others (Epidural and Intrathecal)
• By Regions Insights (Revenue, US$ Mn, 2020 - 2033)
o Brazil
• Key Players
o Becton, Dickinson and Company
o Pfizer Inc.
o Novo Nordisk A/S
o Gerresheimer AG
o Braun Medical Inc.
o Grifols S.A
o Baxter International, Inc.
o Fresenius Kabi AG
o Mylan N.V.
o Bayer AG
o Hoffmann-La Roche AG
o Farmoquimica S.A.
o Novartis International AG
o Eli Lily and Company
o Uniao Química Farmacêutica
o Nacional S.A.
o Cristalia
o Aspen Pharmacare Holdings Limited
o Blau Farmaceutica S.A.
o Halex Istar Indústria
o Farmaceutica SA
o Eurofarma
o Ache Laboratorios Farmaceuticos SA
o Laboratorio Teuto Brasileiro S/A
o EMS Pharma
o Hipolabor Farmaceutica Ltda.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Product Type
Market Snippet, By Drug Class
Market Snippet, By Mode of Delivery
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Product approval and launches
o Merges and Acquisitions
o Key development
o Brazil drug approval process
o Regulatory Scenario
o Reimbursement Scenario
o Brand Analysis
o PEST Analysis
o Pricing Analysis
o Technology Advancement
4. Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Product Type, 2020 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, 2020 and 2033 (%)
Y-o-Y Growth Analysis, 2020 – 2033
Segment Trends
o Pre-filled syringes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Auto-injectors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Pre-filled Pens
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Pre-mixed IV Bags
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
5. Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Drug Class, 2020 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, 2020 and 2033 (%)
Y-o-Y Growth Analysis, 2020 – 2033
Segment Trends
o Anesthesia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Antidotes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Antiemetic
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Anti-infective
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Anti-Thrombolytic
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Muscle relaxant
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Non Opioids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Opioids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Sedatives
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
6. Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, By Mode of Delivery, 2020 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, 2020 and 2033 (%)
Y-o-Y Growth Analysis, 2020 – 2033
Segment Trends
o Intramuscular (IM)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Intravenous (IV)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Subcutaneous (SC)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
o Others (Epidural and Intrathecal)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020 – 2033, (US$ Mn)
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Becton, Dickinson and Company
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Pfizer Inc.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Novo Nordisk A/S
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Gerresheimer AG
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
B. Braun Medical Inc.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Grifols S.A.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Baxter International, Inc.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Fresenius Kabi AG
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Mylan N.V.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Bayer AG
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
F. Hoffmann-La Roche AG
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Farmoquimica S.A.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Novartis International AG
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Eli Lily and Company
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Uniao Química Farmacêutica
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Nacional S.A.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Cristalia
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Aspen Pharmacare Holdings Limited
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Blau Farmaceutica S.A.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Halex Istar Indústria
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Farmaceutica SA
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Eurofarma
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Ache Laboratorios Farmaceuticos SA
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Laboratorio Teuto Brasileiro S/A
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
Hipolabor Farmaceutica Ltda.
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
EMS Pharma
o Company highlights
o Product Portfolio
o Key Highlights
o Financial performance
o Strategies
8. Section
o References
o Research Methodology
o About us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們